Published in Photochem Photobiol on November 01, 1993
Photodynamic therapy. J Natl Cancer Inst (1998) 12.83
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93
Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther (2005) 1.52
Cell death pathways in photodynamic therapy of cancer. Cancers (Basel) (2011) 1.45
Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Proc Natl Acad Sci U S A (1998) 0.98
Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev (2015) 0.89
Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int (2012) 0.87
Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation. PLoS One (2012) 0.86
Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate. BMC Genomics (2007) 0.82
Activation of the IL-10 gene promoter following photodynamic therapy of murine keratinocytes. Photochem Photobiol (2001) 0.82
Ischaemia-reperfusion injury in photodynamic therapy-treated mouse tumours. Br J Cancer (2003) 0.78
Photodynamic therapy. J Natl Cancer Inst (1998) 12.83
Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res (1976) 4.60
Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res (1979) 2.51
Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol (1996) 1.95
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res (2001) 1.44
Relationship between misonidazole toxicity and core temperature in C3H mice. Radiat Res (1979) 1.32
Establishment of a Chinese hamster ovary cell line that expresses grp78 antisense transcripts and suppresses A23187 induction of both GRP78 and GRP94. J Cell Physiol (1992) 1.27
Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res (2000) 1.26
Energetics and efficiency of photoinactivation of murine tumor cells containing hematoporphyrin. Cancer Res (1976) 1.22
Clinical and preclinical photodynamic therapy. Lasers Surg Med (1995) 1.22
Photoinactivation of Chinese hamster cells by hematoporphyrin derivative and red light. Photochem Photobiol (1980) 1.07
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys (1979) 1.06
Photodynamic therapy mediated induction of early response genes. Cancer Res (1994) 1.01
Comparison of mutagenicity and induction of sister chromatid exchange in Chinese hamster cells exposed to hematoporphyrin derivative photoradiation, ionizing radiation, or ultraviolet radiation. Cancer Res (1983) 0.98
Increased photosensitivity in HL60 cells expressing wild-type p53. Photochem Photobiol (1997) 0.95
Systemic toxicity in mice induced by localized porphyrin photodynamic therapy. Cancer Res (1990) 0.94
Acute skin response in albino mice following porphyrin photosensitization under oxic and anoxic conditions. Photochem Photobiol (1984) 0.90
Photodynamic therapy of intraocular tumors: examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue. Cancer Res (1985) 0.89
Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. Cancer Res (2000) 0.89
Tissue distribution of 3H-hematoporphyrin derivative in athymic "nude" mice heterotransplanted with human retinoblastoma. Invest Ophthalmol Vis Sci (1982) 0.89
Decreased expression and function of alpha-2 macroglobulin receptor/low density lipoprotein receptor-related protein in photodynamic therapy-resistant mouse tumor cells. Cancer Res (1995) 0.89
The evolution of photodynamic therapy techniques in the treatment of intraocular tumors. Photochem Photobiol (1987) 0.87
Differential photosensitivity in wild-type and mutant p53 human colon carcinoma cell lines. J Photochem Photobiol B (1998) 0.86
Photosensitization with derivatives of chlorin p6. J Photochem Photobiol B (1995) 0.85
Observations in studies of quantitative kinetics of tritium labelled hematoporphyrin derivatives (HpDI and HpDII) in the normal and neoplastic rat brain model. J Neurooncol (1984) 0.85
The hypoxic cell sensitizer programme in the United States. Br J Cancer Suppl (1978) 0.84
Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. Cancer Res (1992) 0.84
DNA damage and repair in CHO cells following hematoporphyrin photoradiation. Cancer Lett (1980) 0.84
Hematoporphyrin derivative photoradiation induced damage to normal and tumor tissue of the pigmented rabbit eye. Curr Eye Res (1984) 0.83
The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis. Br J Cancer (1987) 0.83
Ineffective photodynamic therapy (PDT) in a poorly vascularized xenograft model. Br J Cancer (1988) 0.82
Hematoporphyrin derivative photoradiation therapy for the treatment of intraocular tumors: examination of acute normal ocular tissue toxicity. Cancer Res (1983) 0.81
Direct comparison of in-vitro and in-vivo Photofrin-II mediated photosensitization using a pulsed KTP pumped dye laser and a continuous wave argon ion pumped dye laser. Lasers Surg Med (1991) 0.81
Expression of potentially lethal damage in Chinese hamster cells exposed to hematoporphyrin derivative photodynamic therapy. Cancer Res (1986) 0.79
Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function. Cancer Res (1999) 0.78
Examination of potentially lethal damage in cells treated with hematoporphyrin derivative and red light. Adv Exp Med Biol (1985) 0.78
Isolation and initial characterization of mouse tumor cells resistant to porphyrin-mediated photodynamic therapy. Cancer Res (1991) 0.78
Adriamycin resistance in Chinese hamster fibroblasts following oxidative stress induced by photodynamic therapy. Photochem Photobiol (1993) 0.78
In vitro and in vivo light dose rate effects related to hematoporphyrin derivative photodynamic therapy. Cancer Res (1985) 0.77
Laser-induced hyperthermia of ocular tumors. Appl Opt (1989) 0.77
The influence of sodium pentobarbital anesthesia on in vivo photodynamic therapy. Photochem Photobiol (1987) 0.76
What makes a good photosensitizer for photodynamic therapy? J Photochem Photobiol B (1988) 0.76
The demonstration of in vivo misonidazole tumour toxicity using post radiation hypoxia. Br J Cancer Suppl (1978) 0.75
Examination of action spectrum, dose rate and mutagenic properties of hematoporphyrin derivative photoradiation therapy. Prog Clin Biol Res (1984) 0.75
Tissue concentrations of doxorubicin in animal models with engrafted intraocular tumours. In Vivo (1992) 0.75
Recent developments in the genetics and treatment of retinoblastoma. Birth Defects Orig Artic Ser (1982) 0.75
Acute skin phototoxicity in hairless mice following exposure to crude shale oil or natural petroleum oil. Toxicology (1980) 0.75
Action spectrum (620-640 nm) for hematoporphyrin derivative induced cell killing. Photochem Photobiol (1984) 0.75
Documentation of radioactive contaminants in tritium labeled hematoporphyrin derivative. Prog Clin Biol Res (1984) 0.75
Preclinical evaluation of hematoporphyrin derivative for the treatment of intraocular tumors: a preliminary report. Adv Exp Med Biol (1983) 0.75